ACB $7.560 (-0.13%)

ACNNF $0.251 (-1.67%)

AERO $1.330 (6.4%)

AGEEF $0.421 (-1.95%)

ALEAF $0.967 (-0.34%)

AMMJ $0.285 (-2.23%)

APHA $6.790 (-2.44%)

ARNA $55.320 (-2.09%)

ATT:CNX $0.080 (0%)

ATTBF $0.032 (-2.57%)

AUSA:CNX $1.010 (-0.98%)

AUSAF $0.760 (-0.2%)

AVXL $3.060 (-6.99%)

BAMM:CNX $1.400 (23.89%)

BBM:CNX $0.400 (-4.76%)

BBRRF $0.302 (-2.58%)

BE:CNX $0.085 (6.25%)

BIO:CNX $0.530 (6%)

BLEVF $0.063 (0.48%)

BLIS:CNX $0.380 (0%)

BLO:CNX $1.220 (1.67%)

BLOZF $0.910 (1.79%)

BUDZ $0.610 (-7.53%)

BXNG $0.440 (-5.35%)

CADMF $1.310 (3.45%)

CALI:CNX $0.130 (8.33%)

CANN $0.865 (0.58%)

CARA $19.370 (-2.96%)

CBII:CNX $0.165 (3.13%)

CBWTF $0.563 (-4.34%)

CGC $41.180 (-1.62%)

CGRW $0.420 (0%)

CHOO:CNX $0.490 (2.08%)

CHOOF $0.360 (1.41%)

CNAB $0.360 (-3.16%)

CNBX $0.293 (-2.47%)

CNGGF $1.290 (-8.51%)

CODI $19.080 (0.63%)

CPMD $1.830 (7.02%)

CRBP $6.850 (-3.52%)

CRON $15.440 (-5.62%)

CROP:CNX $0.220 (4.76%)

CRTPF $3.850 (1.32%)

CRXPF $0.160 (3.39%)

CSI:CNX $1.740 (2.35%)

CTST $5.000 (0%)

CURR $3.950 (6.76%)

CVSI $4.200 (-2.78%)

DIGP $0.160 (8.11%)

DXBRF $0.745 (6.43%)

EAPH $0.005 (-8.16%)

EAT:CNX $0.200 (8.11%)

EEVVF $0.309 (2.01%)

EMHTF $2.140 (-5.31%)

EPWCF $0.122 (0%)

EVIO $0.225 (6.13%)

FFRMF $0.072 (2.55%)

FFT:CNX $0.100 (5.26%)

FNNZF $0.098 (-0.71%)

FSDDF $0.137 (-7.8%)

GGTTF $0.361 (-0.24%)

GLDFF $0.061 (-0.65%)

GLH:CNX $0.075 (0%)

GLNNF $0.103 (-1.9%)

GNBT $1.860 (3.91%)

GRIN:CNX $0.225 (-6.25%)

GRWG $3.020 (-1.31%)

GSTR:CNX $0.170 (-15%)

GTBIF $9.780 (-6.86%)

GTII:CNX $13.150 (-5.94%)

GWPH $170.880 (-2.77%)

HC:CNX $0.310 (-6.06%)

HEXO $5.610 (-4.92%)

HHPHF $0.230 (-8.51%)

HLSPY $0.600 (0%)

HMLSF $13.691 (-1.74%)

HMPPF $0.621 (0.65%)

HRVOF $0.500 (-1.68%)

HSTRF $0.276 (-7.52%)

HUGE:CNX $0.180 (-5.26%)

IAN:CNX $4.200 (-3.67%)

IGC $1.260 (48.22%)

IGXT $0.530 (0%)

IIPR $108.480 (7.5%)

IMLFF $0.264 (-2.22%)

INQD $0.022 (-0.9%)

INSY $0.340 (-15%)

IONC:CNX $0.355 (-6.58%)

ISOL:CNX $1.010 (-2.88%)

ISOLF $0.759 (-2.69%)

ITHUF $3.140 (-4.22%)

IVITF $0.314 (-3.11%)

JWCAF $0.595 (-0.5%)

KALTF $0.038 (7.04%)

KBEV:CNX $0.340 (-5.56%)

KBEVF $0.259 (-4.7%)

KHRNF $1.840 (-6.26%)

KSHB $4.440 (-2.42%)

LDS:CNX $0.385 (2.67%)

LDSYF $0.285 (-0.25%)

LHS:CNX $0.570 (-5%)

LHSIF $0.434 (-4.74%)

LOVE:CNX $0.170 (3.03%)

LVWL:CNX $0.740 (0%)

LXLLF $0.550 (0%)

LXRP $0.868 (2.07%)

LXX:CNX $1.160 (1.75%)

MCIG $0.057 (-1.21%)

MDCL $3.910 (0.51%)

MEDIF $4.057 (5.35%)

MGWFF $0.095 (-4.9%)

MICWF $0.222 (-3.89%)

MJ:CNX $0.425 (-1.16%)

MJNA $0.057 (-1.21%)

MNTR $0.336 (-10.37%)

MRRCF $0.522 (-1.6%)

MWM:CNX $0.300 (0%)

MYM:CNX $0.300 (-3.23%)

MYMMF $0.224 (-2.83%)

NCNNF $0.674 (1.64%)

NDVAF $0.281 (1.67%)

NGW:CNX $0.330 (3.13%)

NRXCF $0.055 (0%)

NSPDF $0.086 (-0.58%)

NTEC $4.720 (-0.63%)

NVTQF $0.013 (0%)

NWKRF $0.424 (0%)

NXGWF $0.243 (0.54%)

NXTTF $0.490 (-3.07%)

OGI $6.270 (-7.79%)

OH:CNX $7.950 (-3.17%)

ORHOF $5.920 (-4.01%)

OWCP $0.016 (-2.5%)

PHGI:CNX $0.340 (-10.53%)

PHGRF $0.274 (-5.62%)

PHVAF $0.320 (-3.03%)

PILL:CNX $0.700 (2.94%)

PKG:CNX $0.235 (-6%)

PLPRF $3.208 (-0.36%)

PLUS:CNX $4.300 (-1.15%)

PMCB $0.039 (0.78%)

PNPL $0.500 (0%)

POTN $0.079 (1.79%)

PRCNF $0.092 (-16.27%)

PTNYF $0.177 (-7.15%)

PUFXF $0.264 (-8.01%)

QCA:CNX $0.205 (-2.38%)

RDDTF $0.713 (-0.63%)

RLLVF $0.067 (2.42%)

RMHB $0.053 (0.19%)

RQB:CNX $0.560 (-1.75%)

RQHTF $0.210 (0.62%)

RVVQF $0.420 (-2.26%)

SLNG:CNX $1.530 (-4.38%)

SMG $96.560 (1.79%)

SNN:CNX $2.960 (-1.99%)

SNNVF $2.209 (-3.1%)

SOL:CNX $2.150 (4.37%)

SOLCF $1.600 (3.23%)

SPLIF $0.141 (2.85%)

SPRWF $1.207 (-3.43%)

SRNA $0.047 (15.56%)

STEM:CNX $2.000 (1.01%)

STMH $1.520 (1.33%)

SUN:CNX $0.610 (1.67%)

TBPMF $0.384 (-5.44%)

TCAN:CNX $4.750 (9.2%)

TDRYF $0.309 (0%)

TER:CNX $5.980 (-1.97%)

TGEN $3.500 (-4.3%)

TGIF:CNX $0.445 (1.14%)

TGIFF $0.334 (0.75%)

THC:CNX $0.255 (-1.92%)

THCBF $0.191 (-3.29%)

TLRY $39.010 (-4.15%)

TOKI:CNX $0.125 (8.7%)

TRLFF $0.318 (-0.87%)

TRPX $2.690 (1.51%)

TRSSF $4.470 (-2.45%)

TRTC $0.630 (-3.82%)

TURV $0.450 (-2.17%)

VAPN:CNX $1.900 (3.83%)

VBIO $0.240 (-4%)

VIDA:CNX $0.425 (-1.16%)

VIN:CNX $0.520 (0%)

VPRB $0.053 (-1.85%)

VRNDF $0.907 (-0.77%)

VRT:CNX $0.390 (5.41%)

VRTHF $0.296 (6.25%)

VVCIF $0.445 (-2.41%)

WAYL:CNX $0.740 (0%)

WDDMF $1.140 (-3.06%)

WLDFF $0.453 (-1.43%)

XXII $1.960 (-2.97%)

ZDPY $0.300 (0%)

ZYNE $13.030 (-4.4%)

Technical420 Site Search

Returned 17 result(s).

Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced that researchers at The Scripps Research Institute and the University of Maryland have generated preclinical…

9 Cannabis Company Updates You Need To Know

The Canadian cannabis sector has been trending higher and came off its recent lows. This has caught the attention of cannabis investors and we are closely monitoring how the sector trades this week.Over the last week, several significant company announcements have been reported and today, we have highlighted nine important…

Zynerba Announces Negative Top-Line Results

GW Pharmaceuticals (GWPH) is an industry leader for a reason…Developing cannabis-based pharmaceutical treatments is not as easy as it looks and Zynerba Pharmaceuticals (ZYNE) is learning that the hard way.Zynerba is trading considerably lower after reporting negative top-line results from its double-blind placebo controlled Phase 2 clinical trial evaluating ZYN002…

Biotech Earnings, Updates, and a Major Acquisition Closes

Medical cannabis has the potential to improve the daily lives of millions of people throughout the world. For that reason alone, the biotech sector will be one of the greatest beneficiaries of the legal cannabis movement.Medical cannabis has the ability to treat countless debilitating and untreatable conditions and this has…

Biotech Stocks Continues To Climb Higher

Although Canadian companies levered to the emerging legal cannabis industry stole the headlines yesterday, Nasdaq-traded biotech firms focused on cannabis-based treatments continued to announce important developments.Two companies on our watch list, Insys Therapeutics (INSY) and Zynerba Pharmaceuticals (ZYNE) were two of the biggest movers yesterday, rallying 7.7% and 4.4%, respectively.New…

Corporate Update: Zynerba Continues To Execute

Zynerba Pharmaceuticals (ZYNE) reported fourth quarter and full-year financial results for the period that ended on December 31st and provided an overview of recent operational highlights.Operational Highlights Show Continued Execution We have been favorable on Zynerba’s ability to execute and follow through on previously announced initiatives. During the last year,…

Big Biotech Plays Continue To Look Attractive

Despite favorable economic data global markets recorded mixed movements which we believe was is the result of investors preparing for an interest rate hike this week.Since one of the hottest sub-sectors of the cannabis industry was impacted by this volatility we think this weakness has created an opportunity for investors.Although…

Cannabis Stock Trends and Opportunities: Banking on Biotech Part 2

Agencies across the globe continue to recognize the medical benefits associated with cannabis. It is only a matter of time before this incredible plant will be legalized in the United States.From the National Cancer Institute (NCI) to the National Institute on Drug Abuse (NIDA), the medical benefits associated with cannabis…

Cannabis Stock Trends and Opportunities: Finding Value in a Down Market

Despite favorable state-wide election results, concerns among cannabis investors have increased and cannabis stocks continue to move lower following an overextended industry wide rally as well as highly questionable cabinet nominations by president elect Donald Trump.Although the recent downward trend is concerning, this weakness has created an opportunity for investors…

3 Overlooked Benefits of Cannabis that Could Improve Life for Millions

Biotech stocks levered to the cannabis industry have been trading soft over the last month following the DEA’s decision not to reschedule cannabis out of its current Schedule I status.Even though marijuana clearly has medical benefits, it remains a Schedule I substance alongside heroin, LSD, ecstasy, and bath salts under…

Older Posts »

Search Again